Real-world immuno-oncology (IO) therapy treatment patterns and outcomes in patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) in the United States

X. Pan; M. M. Lin; Y. Yin; P. Hou; P. Baumann; M. Jahanzeb

doi:10.1093/annonc/mdz063.037

Real-world immuno-oncology (IO) therapy treatment patterns and outcomes in patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) in the United States

X. Pan, M. M. Lin, Y. Yin, P. Hou, P. Baumann, M. Jahanzeb

Medicine

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	ii52-ii53
Journal	Annals of Oncology
Volume	30
DOIs	https://doi.org/10.1093/annonc/mdz063.037
State	Published - Apr 2019

ASJC Scopus subject areas

Hematology
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/annonc/mdz063.037

Cite this

Real-world immuno-oncology (IO) therapy treatment patterns and outcomes in patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) in the United States. / Pan, X.; Lin, M. M.; Yin, Y.; Hou, P.; Baumann, P.; Jahanzeb, M.

In: Annals of Oncology, Vol. 30, 04.2019, p. ii52-ii53.

Research output: Contribution to journal › Article › peer-review

@article{bb3c198f8dbc479b81303ec1c0f9f884,

title = "Real-world immuno-oncology (IO) therapy treatment patterns and outcomes in patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) in the United States",

author = "X. Pan and Lin, {M. M.} and Y. Yin and P. Hou and P. Baumann and M. Jahanzeb",

year = "2019",

month = apr,

doi = "10.1093/annonc/mdz063.037",

language = "English (US)",

volume = "30",

pages = "ii52--ii53",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - Real-world immuno-oncology (IO) therapy treatment patterns and outcomes in patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) in the United States

AU - Pan, X.

AU - Lin, M. M.

AU - Yin, Y.

AU - Hou, P.

AU - Baumann, P.

AU - Jahanzeb, M.

PY - 2019/4

Y1 - 2019/4

UR - http://www.scopus.com/inward/record.url?scp=85079638833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85079638833&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdz063.037

DO - 10.1093/annonc/mdz063.037

M3 - Article

C2 - 32131278

VL - 30

SP - ii52-ii53

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

ER -

Real-world immuno-oncology (IO) therapy treatment patterns and outcomes in patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) in the United States

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this